Kiromic Biopharma, Inc. - FORM S-1 - EX-10.12 - May 11, 2020

Attached files

file filename
EX-23.2 - EX-23.2 - Kiromic Biopharma, Inc.d853469dex232.htm
EX-14.1 - EX-14.1 - Kiromic Biopharma, Inc.d853469dex141.htm
EX-10.28 - EX-10.28 - Kiromic Biopharma, Inc.d853469dex1028.htm
EX-10.25 - EX-10.25 - Kiromic Biopharma, Inc.d853469dex1025.htm
EX-10.24 - EX-10.24 - Kiromic Biopharma, Inc.d853469dex1024.htm
EX-10.23 - EX-10.23 - Kiromic Biopharma, Inc.d853469dex1023.htm
EX-10.22 - EX-10.22 - Kiromic Biopharma, Inc.d853469dex1022.htm
EX-10.21 - EX-10.21 - Kiromic Biopharma, Inc.d853469dex1021.htm
EX-10.20 - EX-10.20 - Kiromic Biopharma, Inc.d853469dex1020.htm
EX-10.19 - EX-10.19 - Kiromic Biopharma, Inc.d853469dex1019.htm
EX-10.18 - EX-10.18 - Kiromic Biopharma, Inc.d853469dex1018.htm
EX-10.17 - EX-10.17 - Kiromic Biopharma, Inc.d853469dex1017.htm
EX-10.16 - EX-10.16 - Kiromic Biopharma, Inc.d853469dex1016.htm
EX-10.15 - EX-10.15 - Kiromic Biopharma, Inc.d853469dex1015.htm
EX-10.14 - EX-10.14 - Kiromic Biopharma, Inc.d853469dex1014.htm
EX-10.13 - EX-10.13 - Kiromic Biopharma, Inc.d853469dex1013.htm
EX-10.11 - EX-10.11 - Kiromic Biopharma, Inc.d853469dex1011.htm
EX-10.10 - EX-10.10 - Kiromic Biopharma, Inc.d853469dex1010.htm
EX-10.9 - EX-10.9 - Kiromic Biopharma, Inc.d853469dex109.htm
EX-10.8 - EX-10.8 - Kiromic Biopharma, Inc.d853469dex108.htm
EX-10.7 - EX-10.7 - Kiromic Biopharma, Inc.d853469dex107.htm
EX-10.6 - EX-10.6 - Kiromic Biopharma, Inc.d853469dex106.htm
EX-10.5 - EX-10.5 - Kiromic Biopharma, Inc.d853469dex105.htm
EX-10.4 - EX-10.4 - Kiromic Biopharma, Inc.d853469dex104.htm
EX-10.3 - EX-10.3 - Kiromic Biopharma, Inc.d853469dex103.htm
EX-10.2 - EX-10.2 - Kiromic Biopharma, Inc.d853469dex102.htm
EX-10.1 - EX-10.1 - Kiromic Biopharma, Inc.d853469dex101.htm
EX-4.1 - EX-4.1 - Kiromic Biopharma, Inc.d853469dex41.htm
EX-3.2 - EX-3.2 - Kiromic Biopharma, Inc.d853469dex32.htm
EX-3.1 - EX-3.1 - Kiromic Biopharma, Inc.d853469dex31.htm
S-1 - S-1 - Kiromic Biopharma, Inc.d853469ds1.htm

Exhibit 10.12

[*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Amendment to License Agreement between CGA 369 Intellectual Holdings, Inc and Kiromic, Inc

Date: October 16, 2019

“Improvements” shall mean any patent application that are developed by an inventor which if practiced would infringe or be necessary or useful in the practice of any of the Licensed Patents. For clarity, Improvements are included as a Licensed Patents, if any new IP or know-how is either developed, discovered, or applied as a result of utilizing, implementing, or incorporating the licensed technology of which the new IP will be the sole property of the Licensee.

3.1. License Fee.

Conditioned upon the result of a sublicense with a third-party entity an upfront fee of no less than *. COMPANY shall pay LICENSOR a one-time payment of no less than * (collectively “Conditions for License Fee”).

 

CGA 369 INTELLECTUAL HOLDINGS INC
By:   /s/ David Aguilar
Name:   David Aguilar
Title:   President/CEO
Kiromic
By:   /s/ Maurizio Chiriva-Internati
Name:   Maurizio Chiriva-Internati
Title:   CEO

Kiromic Biopharma, Inc. Reports